Company: BDRX
Filing Date: 2025-01-08
Form Type: 424B3
Source: 0001214659-25-000302
Chunk: 94

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-08
Form: 424B3
Chunk 94
---
 to time)), 
 or otherwise in any way relating to the constitution or conduct of the Company.                                                 |

| 146.2 | Unless the Company consents in writing to the selection of an alternative forum, the federal district                                 
 courts of the United States of America shall be the sole and exclusive forum for the resolution of any complaint asserting a cause of 
 action arising under the United States Securities Act of 1933, as amended or any successor thereto.                                   |

| 146.3 | For the avoidance of doubt, nothing contained in this Article 146 shall apply to any action brought to                              
 enforce a duty or liability created by the United States Securities Exchange Act of 1934 Act, as amended, or any successor thereto. |

| 72 |

Exhibit 10.1

THIS HAS NOT BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE. THIS NOTE HAS BEEN SOLD IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS.

<div align='center'>Biodexa Pharmaceuticals PLC

Promissory Note</div>

Original Principal Amount: $600,000

Issuance Date: December 23, 2024

Number: BDRX-1

FOR VALUE RECEIVED, Biodexa
Pharmaceuticals PLC, a public limited company organized under the laws of England and Wales (the “”), hereby
promises to pay C/M Capital Master Fund, LP, a Delaware limited partnership, or its registered assigns (the “”),
the amount set out above as the Original Principal Amount (as reduced pursuant to the terms hereof pursuant to repayment, redemption or
otherwise, the “”), in each case when due, and to pay interest (“”) on any outstanding
Principal at the applicable Interest Rate (as defined below) from the date set out above as the Issuance Date (the “”) until the same becomes due and payable, whether upon the Maturity Date or acceleration, redemption or